Patents by Inventor Timothy Heffernan

Timothy Heffernan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20190031651
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: October 5, 2018
    Publication date: January 31, 2019
    Inventors: Richard Thomas LEWIS, Philip JONES, Alessia PETROCCHI, Naphtali REYNA, Matthew HAMILTON, Michael J. SOTH, Timothy HEFFERNAN, Michelle HAN, Jason P. BURKE
  • GLS1 inhibitors for treating disease
    Patent number: 10125128
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: November 13, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard Thomas Lewis, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Matthew Hamilton, Michael J. Soth, Timothy Heffernan, Michelle Han, Jason P. Burke
  • TUNABLE ENDOGENOUS PROTEIN DEGRADATION
    Publication number: 20180179522
    Abstract: The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 28, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Dennis Buckley, Georg Winter, Andrew J. Phillips, Timothy Heffernan, James Bradner, Justin Roberts, Behnam Nabet
  • TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES
    Publication number: 20180169109
    Abstract: This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 21, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Justin Roberts, Behnam Nabet, Georg Winter, Andrew J. Phillips, Timothy Heffernan, Dennis Buckley
  • GLS1 inhibitors for treating disease
    Patent number: 9809588
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: November 7, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20170291895
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 12, 2017
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20170001996
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: June 30, 2016
    Publication date: January 5, 2017
    Inventors: Richard Thomas Lewis, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Matthew Hamilton, Michael J. Soth, Timothy Heffernan, Michelle Han, Jason P. Burke
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20160009704
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 2, 2015
    Publication date: January 14, 2016
    Applicant: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20160002248
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 2, 2015
    Publication date: January 7, 2016
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maria Emilia Di Francesco, Timothy Heffernan, Michael J. Soth, Kang Le, Christopher Lawrence Carroll, Timothy McAfoos, Jason P. Burke, Jay Theroff, Zhijun Kang, Philip Jones
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20160002204
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 3, 2015
    Publication date: January 7, 2016
    Applicant: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Christopher Lawrence Carroll, Timothy McAfoos, Wylie Palmer, Zachary Herrera
  • Methods of Treatment of Chromite Ore Processing Residue
    Publication number: 20070224097
    Abstract: Methods to reduce hexavalent chromium (Cr(VI)) in chromite processing wastes include one or more of the following steps: contacting the chromite processing wastes with an oxygen scavenger or chemical reducer; permitting the chromite processing wastes to react with the oxygen scavenger or chemical reducer; contacting the chromite processing wastes with ferrous ion; contacting the chromite processing wastes with sulfide ion; and, contacting the chromite processing wastes with ferrous sulfide.
    Type: Application
    Filed: September 7, 2005
    Publication date: September 27, 2007
    Applicant: REDOX SOLUTIONS, LLC.
    Inventors: Steven Chisick, Timothy Heffernan, Thomas McCullough, Gary Meyer